Arcus Biosciences Announces New Employment Inducement Grants
24 Dezembro 2021 - 6:10PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused
biopharmaceutical company working to create best-in-class cancer
therapies, today announced that the Compensation Committee of the
Company’s Board of Directors granted four new employees options to
purchase a total of 23,400 shares of the Company’s common stock at
an exercise price per share of $44.59, which was the closing price
on December 23, 2021. The stock options were granted pursuant to
the Company’s 2020 Inducement Plan, which was approved by the
Company’s Board of Directors in January 2020 pursuant to the
“inducement exception” under NYSE Listed Company Manual Rule
303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
partners, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well characterized biology and pathways and studying novel,
biology-driven combinations that have the potential to help people
with cancer live longer. Founded in 2015, the company has expedited
the development of six investigational medicines into clinical
studies, including new combination approaches that target TIGIT,
PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently,
HIF-2alfa. For more information about Arcus Biosciences’ clinical
and pre-clinical programs, please visit www.arcusbio.com or follow
us on Twitter.
Inducement PR
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211224005014/en/
Investor and Media Inquiries: Holli Kolkey VP of
Corporate Communications (650) 922-1269 hkolkey@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024